scholarly journals Zinc-finger transcription factor Slug contributes to the function of the stem cell factor c-kit signaling pathway

Blood ◽  
2002 ◽  
Vol 100 (4) ◽  
pp. 1274-1286 ◽  
Author(s):  
Jesus Pérez-Losada ◽  
Manuel Sánchez-Martı́n ◽  
Arancha Rodrı́guez-Garcı́a ◽  
Maria Luz Sánchez ◽  
Alberto Orfao ◽  
...  

The stem cell factor c-kit signaling pathway (SCF/c-kit) has been previously implicated in normal hematopoiesis, melanogenesis, and gametogenesis through the formation and migration of c-kit+ cells. These biologic functions are also determinants in epithelial–mesenchymal transitions during embryonic development governed by the Snail family of transcription factors. Here we show that the activation of c-kit by SCF specifically induces the expression of Slug, a Snail family member. Slug mutant mice have a cell-intrinsic defect with pigment deficiency, gonadal defect, and impairment of hematopoiesis. Kit+ cells derived from Slug mutant mice exhibit migratory defects similar to those of c-kit+ cells derived from SCF and c-kit mutant mice. Endogenous Slug is expressed in migratory c-kit+ cells purified from control mice but is not present in c-kit+cells derived from SCF mutant mice or in bone marrow cells from W/Wv mice, though Slug is present in spleen c-kit+ cells of W/Wv (mutants expressing c-kit with reduced surface expression and activity). SCF-induced migration was affected in primary c-kit+ cells purified from Slug−/− mice, providing evidence for a role of Slug in the acquisition of c-kit+ cells with ability to migrate. Slug may thus be considered a molecular target that contributes to the biologic specificity to the SCF/c-kit signaling pathway, opening up new avenues for stem cell mobilization.

Author(s):  
Lin Ding ◽  
Zhuang Wu ◽  
Tianju Liu ◽  
Matthew Ullenbruch ◽  
Jianhua Liu ◽  
...  

2010 ◽  
Vol 88 ◽  
pp. 0-0 ◽  
Author(s):  
A ABU EL ASRAR ◽  
S STRUYF ◽  
G OPDENAKKER ◽  
J VAN DAMME ◽  
K GEBOES

2021 ◽  
Vol 24 (4) ◽  
Author(s):  
Hui Li ◽  
Wen Cao ◽  
Xun-Bin Zhang ◽  
Xi-Xia Zhang ◽  
Chao Gu ◽  
...  

2004 ◽  
Vol 279 (45) ◽  
pp. 46706-46714 ◽  
Author(s):  
Alfonso Catalano ◽  
Sabrina Rodilossi ◽  
Maria Rita Rippo ◽  
Paola Caprari ◽  
Antonio Procopio

Cytokine ◽  
2013 ◽  
Vol 61 (1) ◽  
pp. 329-335 ◽  
Author(s):  
Renaud Geslain ◽  
Shahab Uddin ◽  
Hui Liu ◽  
Hongmei Jiang ◽  
Koen van Besien ◽  
...  

2018 ◽  
Vol 36 ◽  
pp. e294-e295
Author(s):  
Muhammad Nabeel Dookhun ◽  
Hai-Lan Zhong ◽  
Ya-Li Sun ◽  
Xiao-Qian Cao ◽  
Hua-Yi Yang Zou ◽  
...  

1998 ◽  
Vol 16 (8) ◽  
pp. 2601-2612 ◽  
Author(s):  
A Weaver ◽  
J Chang ◽  
E Wrigley ◽  
E de Wynter ◽  
P J Woll ◽  
...  

PURPOSE This was the first randomized study to investigate the efficacy of peripheral-blood progenitor cell (PBPC) mobilization using stem-cell factor (SCF) in combination with filgrastim (G-CSF) following chemotherapy compared with filgrastim alone following chemotherapy. PATIENTS AND METHODS Forty-eight patients with ovarian cancer were treated with cyclophosphamide and randomized to receive filgrastim 5 microg/kg alone or filgrastim 5 microg/kg plus SCF. The dose of SCF was cohort-dependent (5, 10, 15, and 20 microg/kg), with 12 patients in each cohort, nine of whom received SCF plus filgrastim and the remaining three patients who received filgrastim alone. On recovery from the WBC nadir, patients underwent a single apheresis. RESULTS SCF in combination with filgrastim following chemotherapy enhanced the mobilization of progenitor cells compared with that produced by filgrastim alone following chemotherapy. This enhancement was dose-dependent for colony-forming unit-granulocyte-macrophage (CFU-GM), burst-forming unit-erythrocyte (BFU-E), and CD34+ cells in both the peripheral blood and apheresis product. In the apheresis product, threefold to fivefold increases in median CD34+ and progenitor cell yields were obtained in patients treated with SCF 20 microg/kg plus filgrastim compared with yields obtained in patients treated with filgrastim alone. Peripheral blood values of CFU-GM, BFU-E, and CD34+ cells per milliliter remained above defined threshold levels longer with higher doses of SCF. The higher doses of SCF offer a greater window of opportunity in which to perform the apheresis to achieve high yields. CONCLUSION SCF (15 or 20 microg/kg) in combination with filgrastim following chemotherapy is an effective way of increasing progenitor cell yields compared with filgrastim alone following chemotherapy.


Sign in / Sign up

Export Citation Format

Share Document